KZR Kezar Life Sciences
- 0.857
- +0.003+0.32%
- 0.833
- -0.024-2.85%
Kezar Life Sciences News
13 Best Penny Stocks to Buy According to Billionaire Ken Griffin
Analysts' Opinions Are Mixed on These Healthcare Stocks: Kezar Life Sciences (KZR), Fisher & Paykel Healthcare Corporation Limited (OtherFSPKF) and Cue Health (HLTH)
Kezar Life Sciences: KZR-261 Dose Escalation Study Currently Enrolling 9th Cohort>KZR
Kezar Life Sciences: KZR-261 Dose Escalation Study Currently Enrolling 9th Cohort>KZR
Express News | Kezar Life Sciences Q4 EPS $(0.44) Misses $(0.38) Estimate
Kezar Life Sciences Still Expects Topline Data From Lupus Nephritis Treatment Trial In Mid-2026>KZR
Kezar Life Sciences Still Expects Topline Data From Lupus Nephritis Treatment Trial In Mid-2026>KZR
Kezar Life Sciences 4Q Loss/Shr 44c >KZR
Kezar Life Sciences 4Q Loss/Shr 44c >KZR
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the Compensation Committee of the
Kezar Life Sciences to Participate in the TD Cowen 44th Annual Health Care Conference
Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that Chris Kirk, Co-founder and Chief
Reported Late Monday, Everest Medicines And Kezar Life Sciences Received IND Approval From China's NMPA For The PALIZADE Trial In Lupus Nephritis
Everest Medicines (HKEX 1952.HK) and Kezar Life Sciences, Inc. (NASDAQ:KZR) announced today that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) approve
Everest Medicines and Kezar Life Sciences Receive IND Approval From China NMPA for PALIZADE Trial in Lupus Nephritis
Everest Medicines (HKEX 1952.HK) and Kezar Life Sciences, Inc. (Nasdaq: KZR) announced today that the Center for Drug Evaluation (CDE) of China's...
As Oversupply Deflates Lithium Bubble, IPO Market Keeps In High Spirits
The lithium market is facing persistent turmoil as spot prices have continuously declined for more than a year. Supply shortages and speculation caused a lithium bubble in 2022, with spot prices reach
Analysts' Top Healthcare Picks: DocGo (DCGO), Kezar Life Sciences (KZR)
Analyst Expectations for Kezar Life Sciences's Future
Analysts have provided the following ratings for Kezar Life Sciences (NASDAQ:KZR) within the last quarter: BullishSomewhat BullishIndifferentSomewhat BearishBearishTotal Ratings30100Last 30D100001M Ag
Kezar Life Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disor
Kezar Life Sciences Is Maintained at Equal-Weight by Wells Fargo
Kezar Life Sciences Is Maintained at Equal-Weight by Wells Fargo
Wells Fargo Maintains Equal-Weight on Kezar Life Sciences, Lowers Price Target to $2
Wells Fargo analyst Derek Archila maintains Kezar Life Sciences (NASDAQ:KZR) with a Equal-Weight and lowers the price target from $4 to $2.
Hold Rating for Kezar Life Sciences Amid Uncertainty: An Analysis of Management Changes, Drug Trials, and Financial Prospects
Kezar Life Sciences GAAP EPS of -$0.32 Beats by $0.04, Revenue of $7M Beats by $6.7M
Analysts Are Bullish on Top Healthcare Stocks: Antibe Therapeutics (ATBPF), Kezar Life Sciences (KZR)
Express News | Kezar Life Sciences Q3 EPS $(0.32) Beats $(0.35) Estimate, Sales $7.00K
Analysis
Price Target
No Data
